Notice of Results & Presentations

Summary by AI BETAClose X

Diaceutics PLC will announce its unaudited half-year results for the period ended 30 June 2026 on Tuesday, 22 September 2026. An analyst and investor webinar presentation will be held on the same day at 1400 BST. The company, which works with 21 of the top 30 pharmaceutical companies, aims to redefine commercialization for diagnostic-driven therapies.

Disclaimer*

Diaceutics PLC
08 September 2026
 

 

Diaceutics - Notice of Results & Presentations

New York, Belfast and London, 8 September 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, will announce its unaudited results for the half year ended 30 June 2026 on Tuesday, 22 September 2026.

Analyst Presentation:

A webinar presentation for analysts and investors will be held at 1400 BST (0900 EDT) on Tuesday, 22 September 2026. Those wishing to attend can register their interest using the following link:

 

https://us06web.zoom.us/webinar/register/WN_UrTI-vTlSKWPJJwd7_9KlA

 

Enquiries: 

Diaceutics PLC   


Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

 



Canaccord Genuity Limited (Nomad & Broker) 

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees


 

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings